News Archive

The Maryland Department of Commerce is joining with the state’s top research universities and other life sciences partners and stakeholders to create two or more Centers of Excellence around the state to support cell, gene, and regenerative therapies, as well as medical devices and 3-D printing. This partnership with The Johns Hopkins University, the University of Maryland, Baltimore and the University of Maryland, College Park will help position Maryland as a leader in commercialization and clinical translation of next-generation medicines and medical devices and ensure the state remains a leader in healthcare innovation. Additional partners include the Center for Medical Technology Policy and biotechnology, pharmaceutical, contract manufacturing, and medical device companies.

Vibrent Health officials said their efforts will receive $74 million over five years.

In the complex world of children’s cancer research, no independent organization currently coordinates efforts between academic scientists, drug developers, and policy regulators to advance new treatments and cures. Moving forward, CureSearch is proud to play the role of convener and collaborator to bring these key parties together in a way that is singularly focused on accelerating the commercialization of children’s cancer treatments to save children now.

Cleveland is home to more than 700 bioscience companies, a powerful ecosystem that draws strength from a clinical, research and educational foundation dedicated to growth and medical innovation. A new rebranding initiative led by a host of area institutions is ready to send this message out into the world.

Called “The Medical Capital,” the campaign’s centerpiece is a website where visitors can access information regarding biomedical investments and start-up activity in the region. Organizers are also offering a video showcasing the region’s burgeoning tech-based assets, complete with testimonials from investors and CEOs. Social media is another facet of the effort.

Mitre and the University System of Maryland have selected five U.S. academic professionals as recipients of $293,000 in seed grants to conduct studies on cybersecurity challenges, ExecutiveBiz reported Friday.

The company said Thursday the grants went to researchers from George Mason University, University of Maryland in Baltimore, University of Maryland in College Park, University of Texas at San Antonio and University of Alabama at Birmingham.

Roche is rumored to make a move on the California biotech BioMarin. Despite a slightly weakened pipeline, Roche appears undeterred and previous offers were predicted to be around $15Bn.

As big as some of the other industry veterans, BioMarin was founded in the 90’s boom in Biotech in San Rafaele, California. The deal itself is entirely based on rumor and anonymous sources, originally appearing on the blog Betaville.

This is the fifth consecutive year for the USA Creative Business Cup. This year for the first time there will be a f2f finals for competing teams in Washington, DC as part of the activities of Creative World – DC (creativeworld.group) and the National Creativity Network Conference within it. The USA national winner goes on to compete for the 2016 global Creative Business Cup in Copenhagen, Denmark (November 20-21) as a featured event of the 2016 Global Entrepreneurship Week (GEW). It is anticipated that over 60 nations will send teams to compete in this year’s event.

When: July 28th 5:00 p.m. to 7:00 p.m.

Where: BRI 9410 Key West Ave Rockville, MD 20850

Join BioBuzz and July Co-Sponsors BRI and Azzur IT, as we visit BRI’s offices and labs at their new location in Rockville on July 28th. Biomedical Research Institute (BRI), a 501 c 3 non-profit company, which focuses on the development of diagnostic and vaccine solutions to Schistosomiasis, a parasitic disease that impacts sub-Saharan Africa, Brazil and rural Asia where 800 million people live and over 200 million people are infected.

The expanding role of healthcare providers is not limited to societies with “developed” healthcare systems. Diseases, such as AIDS and malaria, prevalent in the third world and emerging countries are now considered chronic or curable with the proper treatment, leaving those afflicted with greater chance of recovery. However, as the cost the typical person pays for healthcare over his or her lifetime rises, the question becomes: How will these emerging societies, especially those in less-developed countries, sustain a rising bill?

After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National Institutes of Health in a project based at its new vaccine research hub in Rockville, MD.